NCT00372593 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 531
- group Id
- BG001
- value
- 532
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1070
- units
- Participants
- groups
- description
- Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG000
- title
- Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome
- description
- Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, \& 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG001
- title
- Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome
- description
- Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG002
- title
- Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 2336.55
- value
- 3352.86
- group Id
- BG001
- spread
- 2283.45
- value
- 3466
- group Id
- BG002
- spread
- 1979.95
- value
- 4206.71
- group Id
- BG003
- spread
- 2310
- value
- 3409.43
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- days
- classes
- categories
- measurements
- group Id
- BG000
- value
- 516
- group Id
- BG001
- value
- 510
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1033
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 37
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 260
- group Id
- BG001
- value
- 277
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 541
- title
- Female
- measurements
- group Id
- BG000
- value
- 271
- group Id
- BG001
- value
- 255
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 529
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 52
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 122
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 383
- group Id
- BG001
- value
- 394
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 782
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 108
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 197
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 834
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 39
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 473
- group Id
- BG001
- value
- 480
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 958
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 68
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 34
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Switzerland
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 531
- group Id
- BG001
- value
- 532
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1070
- units
- Participants
- groups
- description
- Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG000
- title
- Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome
- description
- Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, \& 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG001
- title
- Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome
- description
- Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
- id
- BG002
- title
- Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 2336.55
- value
- 3352.86
- group Id
- BG001
- spread
- 2283.45
- value
- 3466
- group Id
- BG002
- spread
- 1979.95
- value
- 4206.71
- group Id
- BG003
- spread
- 2310
- value
- 3409.43
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- days
- classes
- categories
- measurements
- group Id
- BG000
- value
- 516
- group Id
- BG001
- value
- 510
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1033
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 37
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 260
- group Id
- BG001
- value
- 277
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 541
- title
- Female
- measurements
- group Id
- BG000
- value
- 271
- group Id
- BG001
- value
- 255
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 529
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 52
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 122
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 383
- group Id
- BG001
- value
- 394
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 782
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 108
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 197
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 411
- group Id
- BG001
- value
- 416
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 834
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 39
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 473
- group Id
- BG001
- value
- 480
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 958
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 68
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 34
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Switzerland
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 9
- title
- New Zealand
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle